EQBMED

Through our Action 9 commitment to advance racial equity, McKinsey is supporting the launch of the Equitable Breakthroughs in Medicine Development (EQBMED) program. The EQBMED program aims to develop a patient-centric, scalable model to achieve equity in clinical research for Black, Hispanic, and Latino populations through innovative and sustainable partnerships across patients, communities, clinical trial sites and sponsors of biopharmaceutical research. In its initial 18-month Learning Phase, it will pilot a network of 10 sustainable, connected, community-based trial sites in underserved communities with enhanced infrastructure to enrich clinical trial diversity. The robust program engine, tools, and insights established in this Learning Phase will enable scaling to additional populations, geographies, and sites of care in the future.
 
This program is led in partnership with the Yale School of Medicine, Morehouse School of Medicine, The Research Centers in Minority Institutions (RCMI) Coordinating Center, and Vanderbilt University, and funded by a grant from the Pharmaceutical Research and Manufacturers of America (PhRMA).